Rémi joined the Kurma Partners France as Managing Partner in 2010. He has served on Prosensa supervisory board since 2008.
Rémi Droller started at CDC Innovation from 2000 to 2003, later joining AGF Private Equity (now Idinvest Partners) where he developed the investment activity in the life sciences and made investments such as Novagali Pharma (listed on Euronext and acquired by Santen) Prosensa Therapeutics (listed on Nasdaq and acquired by Biomarin) Vivacta (acquired by Novartis), IntegraGen (listed on Alternext) Onxeo (listed on Euronext).
Rémi joined Kurma Partners in 2010 and is in charge of investments in AM Pharma (The Netherlands), Orphazyme (Denmark), Oxthera (Sweden), Stat Diagnostica (Spain), Step Pharma (France) and Zealand Pharma (Denmark).
Rémi Droller has a Master in Molecular Biology (Paris VI) and Master in Finance and Innovation Management (Masternova - AgroPariTech).